Newswise — MOUNT OLIVE, N.J., Feb. 5, 2019 /PRNewswire/ -- Flowonix Medical, Inc. today announced United States Food and Drug Administration (FDA) approval to market the Flowonix Maestro™ Software for Clinician Programmers used to program Prometra® Pump
"Physicians continue to be drawn to the Prometra System due to its ability to provide consistently accurate dosing using a novel micro-bolus delivery mechanism that delivers
The newly approved Flowonix Maestro Software includes significant
"We are excited to introduce the Flowonix Maestro Software into clinics around the country, as the enhancements included in the software were driven by feedback provided directly by our customers," said Larry Heaton, President and CEO, Flowonix Medical, Inc. "We are confident the combination of the Flowonix Maestro Software and the novel drug delivery mechanism of the Prometra Pump will strengthen our position in the marketplace and set the company up for long-term success in targeted drug delivery.
About the Prometra® II Programmable Infusion System
The Prometra Programmable Infusion Pump System is indicated for intrathecal infusion of drug therapy, including: Infumorph (preservative free morphine sulfate sterile solution), preservative-free sterile 0.9% saline solution (Sodium Chloride Injection, USP), and baclofen (baclofen injection, intrathecal, 500-2000 mcg/mL).
About Flowonix
Flowonix Medical, Inc. (www.
FLOWONIX and PROMETRA are registered trademarks of Flowonix Medical, Inc.
INFUMORPH is a registered trademark of West-Ward Pharmaceuticals.
PL-15111-00
February 2019
CONTACT: Jeff Colella, [email protected]